Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > (AIM:MTPH.L)(Nasdaq:MTP) MTX-110 Ph1 Study Update
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(16)
•••
Comment by narmacon Jan 12, 2023 11:53am
100 Views
Post# 35218597

RE:(AIM:MTPH.L)(Nasdaq:MTP) MTX-110 Ph1 Study Update

RE:(AIM:MTPH.L)(Nasdaq:MTP) MTX-110 Ph1 Study UpdateMTP down to .68 cents this afternoon,,,,,,it lost over half its value since the so called deal was announced,,,,and the news on the MTX110 escalation was seen as a negative. The market hates this company we are been forced to sleep with,,,and it would seem it will hate Biodexa even more!!

I assume the deal will be re-evaluted before Feb, 3rd,,we will be diluted back to 1% or less in that scenario!!

You cant make this stuff up,,,,it cant be sugar coated,,,,,its clearly mindboggling stupidity by both companies,,,,and playing into the hands of 3rd paties!!!,,if we had failed in trial back 5 or 10 years ago we would be well ahaed of the game!!!,,,,,the greed within these two companies is overwhelming!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities